title: Rituximab Use in Pediatric Dermatology.
abstract: Rituximab, an anti CD20 monoclonal antibody leading to transitory B cell depletion, is used to treat a wide variety of immune system tumors and immune mediated diseases. While most of data supporting the efficacy and safety of rituximab in treating autoimmune patients is focused on the adult population, the utilization of rituximab (RTX) for a wide range of pediatric conditions is also increasing. While there are a number of published case reports, a comprehensive review of the various uses for rituximab in pediatric dermatology is lacking. To better assess the therapeutic role of rituximab in the management of skin disease in children, here we comprehensively document reported cases of use including details regarding specific treatment regimens, efficacy and safety profile. Evaluation of the data supports consideration for the initiation of rituximab at early time points in the treatment ladder, before certain diseases become refractory to conventional treatment. <br /><br /> <em>J Drugs Dermatol.</em> 2016;15(7):821-829.
authors.forename: Melissa B
authors.initials: MB
authors.lastname: Hoffman
authors.forename: Rachna A
authors.initials: RA
authors.lastname: Bhandari
authors.forename: Animesh A
authors.initials: AA
authors.lastname: Sinha
mesh_terms: D002648:Child; D003880:Dermatology / Q000379:methods* / Q000639:trends; D004359:Drug Therapy, Combination; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects; D010372:Pediatrics / Q000379:methods* / Q000639:trends; D000069283:Rituximab / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000139:chemically induced; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab